United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. Our lead product, Remodulin, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as Hepatitis C. For more information about United Therapeutics' pipeline, click here

To receive press releases, quarterly and annual SEC filings, please click here.

Current Press Releases

Apr 25, 2013
United Therapeutics Corporation Reports First Quarter 2013 Financial Results

Apr 18, 2013
United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013

more »

Events

May 29, 2013
Deutsche Bank's 2013 Health Care Conference

Jun 3, 2013
Jefferies 2013 Global Healthcare Conference

Jul 30, 2013
BMO Capital Markets Biotech Corporate Access Day - Boston

more »